FibroBiologics begins trading on Nasdaq via direct listing under ticker FBLG

FibroBiologics, Inc.

Direct listing commenced January 31, 2024 on the Nasdaq Global Market.
Stock trades under ticker symbol FBLG.
Company is a clinical-stage biotech focused on fibroblast-based therapies for chronic diseases.
Registration statement on Form S-1 declared effective by SEC on January 24, 2024.
No financial results or operational milestones were disclosed in the announcement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.